FDA Approves Radicava for Amyotrophic Lateral Sclerosis

Share this content:
FDA Approves Radicava for Amyotrophic Lateral Sclerosis
FDA Approves Radicava for Amyotrophic Lateral Sclerosis

MONDAY, May 8, 2017 (HealthDay News) -- The first new drug to treat amyotrophic lateral sclerosis (ALS) in more than 20 years has been approved by the U.S. Food and Drug Administration.

Radicava (edaravone) is taken intravenously daily for 14 days, followed by 14 days without the drug. Subsequent treatment cycles consist of treatment for 10 out of 14 days, followed by 14 days without the drug.

The FDA's approval of Radicava was based on a six-month clinical trial in Japan that included 137 patients who received either the drug or an inactive placebo, the agency said. After 24 weeks, patients taking the drug had less decline in physical functioning than those taking the placebo. The most common side effects among patients taking the drug were bruising and gait disturbance.

"Radicava is also associated with serious risks that require immediate medical care, such as hives, swelling, or shortness of breath, and allergic reactions to sodium bisulfite, an ingredient in the drug," the agency said in the news release. "Sodium bisulfite may cause anaphylactic symptoms that can be life-threatening in people with sulfite sensitivity."

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Herbal and Dietary Supplements Are Commonly Mislabeled

Herbal and Dietary Supplements Are Commonly Mislabeled

Bodybuilding products have highest mislabeling rate; many mislabeled products tied to liver injury

Alcoholic Cirrhosis Linked to Increased Admissions, Costs

Alcoholic Cirrhosis Linked to Increased Admissions, Costs

Compared with non-alcoholic cirrhosis, excess 30-day readmissions total 29.2 per 100 patients

is free, fast, and customized just for you!

Already a member?

Sign In Now »